The neutralization of interferons by antibody III. The constant antibody bioassay, a highly sensitive quantitative detector of low antibody levels

Journal of Interferon and Cytokine Research

Volumn 29, Issue 2, 2009, Pages 93-104

  Grossberg, Sidney E ^a   Kawade, Yoshimi ^b   Grossberg, Leslie D ^a  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

^b KYOTO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

INTERFERON; NEUTRALIZING ANTIBODY; BETA INTERFERON; BETA1A INTERFERON; INTERFERON BETA SERINE;

ANTIBODY BLOOD LEVEL; ANTIBODY TITER; ARTICLE; BIOASSAY; BLOOD SAMPLING; CONTROLLED STUDY; DILUTION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; BLOOD; IMMUNOLOGY; SENSITIVITY AND SPECIFICITY; SERODIAGNOSIS;

ANTIBODIES, NEUTRALIZING; HUMANS; INTERFERON-BETA; NEUTRALIZATION TESTS; SENSITIVITY AND SPECIFICITY;

EID: 59349091260     PISSN: 10799907     EISSN: None     Source Type: Journal    
DOI: 10.1089/jir.2008.0043     Document Type: Article

References (36)

1. Andzhaparidze OG, Ayres JJ, De Maeyer E, Finter N, Friedman R, Grossberg SE, Kramer SM, Laughlin CA, Leibowitz PJ. 1988. WHO Expert Committee on Biological Standardization. 38th report. Annex l. Standardization of interferons: Report of a WHO informal consultation. World Health Organ Tech Rep 771:37-87.
2. rd report. Annex 1. Standardization of Interferons. World Health Organ Tech Rep 687:35-60.
3. Bertolotto A, Sala A, Caldano M, Capobianco M, Malucchi S, Marnetto F, Gilli F. 2007. Development and validation of a real time PCR-based bioassay for quantification of neutralizing antibodies against human interferon-beta. J Immunol Meth 321(1-2):19-31.
4. Bertolotto A, Gilli F, Sala A, Capobianco M, Malucchi S, Milano E, Melis F, Marnetto F, Lindberg RL, Bottero R, Di Sapio A, Giordana MT. 2003. Persistent neutralizing antibodies abolish the interferon beta bioavailability in MS patients. Neurology 60(4):634-639.
5. th report. Annex 1. Standardization of Interferons. World Health Organ Tech Rep 725:28-64.
6. Boz C, Oger J, Gibbs E, Grossberg SE. 2007. Reduced effectiveness of long-term interferon-β treatment of relapses in neutralizing antibody-positive multiple sclerosis patients: A Canadian multiple sclerosis clinic-based study. Mult Scler 13(9):1127-1137.
7. Calam DH, Drozdov SG, Gust ID, Hardegree MC, Lemoine PE, Lyng J, Ofosu FA, Tan I, Hai-Jun Z. 1995. World Health Organization Expert Committee on Biological Standardization. 45th report. Antibodies to Human Interferon alfa and beta. World Health Organ Tech Rep 858:11.
8. Deisenhammer F, Reindl M, Harvey J, Gasse T, Dilitz E, Berger T. 1999. Bioavailability of interferon beta 1b in MS patients with and without neutralizing antibodies. Neurology 52(6):1239-1243.
9. Goodin DS, Frohman EM, Hurwitz B, O'Connor PW, Oger JJ, Reder AT, Stevens JC. 2007. Neutralizing antibodies to interferon beta: Assessment of their clinical and radiographic impact: An evidence report: Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 68(13):977-984.
10. Grossberg SE, Kawade Y. 2006. The development and measurement of antibodies to interferon. In: Meager A, ed. The interferons: characterization and application. Weinheim, Germany: Wiley-VCH Verlag GmbH & Co. pp 375-399.
11. Grossberg SE, Taylor JL, Siebenlist RE, Jameson P. 1986. Biological and immunological assays of human interferons. In: Rose NR, Friedman R, Fahey JL, eds. Manual of clinical immunology, 3rd ed. Washington, DC: ASM Publishing. pp 295-299.
12. Grossberg SE, Kawade Y. 1997. The expression of potency of neutralizing antibodies for interferons and other cytokines. Biotherapy 10(1):93-98.
13. Grossberg SE, Kawade Y, Kohase M, Yokoyama H, Finter N. 2001a. The neutralization of interferons by antibody. I. Quantitative and theoretical analyses of the neutralization reaction in different bioassay systems. J Interferon Cytokine Res 21(9):729-742.
14. Grossberg SE, Kawade Y, Kohase M, Klein JP. 2001b. The neutralization of interferons by antibody. II. Neutralizing antibody unitage and its relationship to bioassay sensitivity: The tenfold reduction unit. J Interferon Cytokine Res 21(9):743-755.
15. Hartung HP, Polman C, Bertolotto A, Deisenhammer F, Giovannoni G, Havrdova E, Hemmer B, Hillert J, Kappos L, Kieseier B, Killestein J, Malcus C, Comabella M, Pachner A, Schellekens H, Sellebjerg F, Selmaj D, Sorensen PS. 2007. Neutralising antibodies to interferon beta in multiple sclerosis: Expert panel report. J Neurol 254(7):827-837.
16. Kawade Y. 1980. An analysis of neutralization reaction of interferon by antibody: a proposal on the expression of neutralization titer. J Interferon Res 1(1):61-70.
17. Kawade Y. 1986. Quantitation of neutralization of interferon by antibody. Meth Enzymol 119:558-573.
18. Kawade Y, Watanabe Y. 1984. Neutralization of interferon by antibody: appraisals of methods of determining and expressing the neutralization titer. J Interferon Res 4(4):571-584.
19. Kawade Y, Watanabe Y. 1985. The nature of neutralization reaction between effector protein and monoclonal antibody: a quantitative study of neutralization characteristics of anti-interferon antibodies. Immunology 56(3):489-495.
20. Kawade Y, Finter N, Grossberg SE. 2003. Neutralization of the biological activity of cytokines and other protein effectors by antibody: theoretical formulation of antibody titration curves in relation to antibody affinity. J Immunol Methods 278(1-2):127-144.
21. Lallemand C, Mariete J, Erickson R, Grossberg SE, Roullet E, Lyon-Caen O, Lebon P, Tovey MG. 2008. Quantification of neutralizing antibodies to human type I interferons using division-arrested frozen cells carrying an interferon-regulated reporter-gene. J Interferon Cytokine Res 28:393-404.
22. Malucchi S, Sala A, Gilli F, Bottero R, Di Sapio A, Capobianco M, Bertolotto A. 2004. Neutralizing antibodies reduce the efficacy of βIFN during treatment of multiple sclerosis. Neurology 62(11):2031-2037.
23. Muller F. 2006. Overview of clinical applications of type I interferons. In: Meager A, ed. The interferons: characterization and application. Weinheim, Germany: Wiley-VCH Verlag GmbH & Co. pp. 277-308.
24. Perini P, Calabrese M, Biasi G, Gallo P. 2004. The clinical impact of interferon beta antibodies in relapsing-remitting MS. J Neurol 251(3):305-309.
25. PRISMS Study Group and the University of British Columbia MS/MRI Analysis Group. 2001. PRISMS-4: Long-term efficacy of interferon-beta-1a in relapsing MS. Neurology 56(12):1628-1636.
26. Pungor E Jr, Files JG, Gabe JD, Do LT, Foley WP, Gray JL, Nelson JW, Nestaas E, Taylor JL, Grossberg SE. 1998. A novel bioassay for the determination of neutralizing antibodies to IFN-beta1b. J Interferon Cytokine Res 18(12):1025-1030.
27. Research Reference Reagent Note No. 35. March, 1987. Freeze-dried reference human interferon beta [HuIFN-beta] catalog number Gb23-902-531.
28. Research Reference Reagent Note No. 37. March, 1987. Freeze-dried reference human recombinant interferon Beta/ser [HuIFN-beta/ser] catalog number Gxb02-901-535.
29. Research Reference Reagent Note No. 44. April, 1994. Freeze-dried human anti-human interferon-alpha antibody reference catalog number G037-501-572.
30. Research Reference Reagent Note No. 45. April, 1994. Freeze-dried human anti-human interferon-beta antibody reference catalog number G038-501-572.
31. Rice G. 2001. The significance of neutralizing antibodies in patients with multiple sclerosis treated with interferon beta. Arch Neurol 58(8):1297-1298.
32. Rice GP, Paszner B, Oger J, Lesaux J, Paty D, Ebers G. 1999. The evolution of neutralizing antibodies in multiple sclerosis patients treated with interferon beta-1b. Neurology 52(6):1277-1279.
33. Sorensen PS, Koch-Henriksen N, Ross C, Clemmesen KM, Bendtzen K, Danish Multiple Sclerosis Study Group. 2005a. Appearance and disappearance of neutralizing antibodies during interferon-beta therapy. Neurology 65(1):33-39.
34. Sorensen PS, Deisenhammer F, Duda P, Hohlfeld R, Myhr KM, Palace J, Polman C, Pozzilli C, Ross C, EFNS Task Force on Anti-IFN-beta Antibodies in Multiple Sclerosis. 2005b. Guidelines on use of anti-IFN-beta antibody measurements in multiple sclerosis: report of an EFNS task force on IFN-beta antibodies in multiple sclerosis. Eur J Neurol 12(11):817-827.
35. The IFNB Multiple Sclerosis Study Group and the University of British Columbia MS/MRI Analysis Group. 1996. Neutralizing antibodies during treatment of multiple sclerosis with interferon beta-1b: Experience during the first three years. Neurology 47(4):889-894.
36. Vallittu AM, Halminen M, Peltoniemi J, Ilonen J, Julkunen I, Salmi A, Eralinna JP, Finnish Beta-Interferon Study Group. 2002. Neutralizing antibodies reduce MxA protein induction in interferon-beta-1a-treated MS patients. Neurology 58(12):1786-1790.